Clinical trials: Hyperlipoproteinemia
Healthy
A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning
In this study, radioactive PF-06427878 will be administered, through a vein, alone and with 2 different oral doses of non-radioactive PF-06427878 to healthy, adult, male subjects.
- Trial name
- NCT02410525
- Testing
- [11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Disease
Smart Watch, Heart Rate and So2 in Chronic Patients
Background: Apple watch validity to measure the heart rate (HR) and oxygen saturation (Spo2) in healthy subjects has been investigated, but its accuracy and validity for patients with chronic non-communicable diseases such as…
- Trial name
- NCT05271864
- Testing
- Apple Watch
- Where
- Saudi Arabia
- Volunteers
- 41 people
- Sponsor
- Umm Al-Qura University
Primary Hypercholesterolaemia, Mixed Hyperlipidaemia
Lipid Efficacy/Tolerability Study (0524A-020)
A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups.
- Trial name
- NCT00269204
- Testing
- niacin (+) laropiprant, ER-niacin
- Volunteers
- 1,620 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
The purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00236626
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hyperlipidemia
Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)
The purpose of this study is to evaluate the bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration.
- Trial name
- NCT01353404
- Testing
- Sequence 1, Sequence 2, Seqeunce 3
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Samyang Biopharmaceuticals Corporation
Hypercholesterolemia
Influence of OATP1B1 and BRCP Genotype on Rosuvastatin PK, PD and Lipidomics in Hyperlipidemic Patients
The aim of this study is to investigate the pharmacokinetics, lipid lowering effect and lipidomic profiles of 8-weeks rosuvastatin treatment by OATP1B1 genotype in hyperlipidemia patients.
- Trial name
- NCT01466608
- Testing
- Rosuvastatin
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Seoul National University Hospital
Hypercholesterolemia, Familial
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Homozygous Familial Hypercholesterolemia
- Trial name
- NCT00280995
- Testing
- ISIS 301012
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 12 people
- Sponsor
- Kastle Therapeutics, LLC
Familial Hypercholesterolemia
Return of Actionable Variants Empirical Study
This is a genomic implementation project with ancillary studies to understand the impact on patients' health and well-being of returning genomic results to them and depositing those results in the medical record.
- Trial name
- RAVE (NCT03640234)
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Overweight; Hyperlipidemia
Efficacy and Safety of Fermented Barley on Decrement of Body Fat in Obese Subjects
Barley, like oats, is a rich source of the soluble fibre β-glucan, which has been shown to significantly lower LDL-cholesterol (LDL-C). However, barley foods have been less widely studied.
- Trial name
- NCT01402128
- Testing
- Barley beta-glucan(3.0g)
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Hyperlipidemias
Effects of Moderate Intensity Intermittent and Moderate Intensity Continuous Training on Hyperlipdemia
This project will be a Randomized control trial conducted to check the effects of moderate intensity intermittent training versus moderate intensity continuous training on indices of cardio-metabolic health in women with…
- Trial name
- NCT05078736
- Testing
- Moderate intensity intermittent training, Moderate intensity continuous training
- Where
- Pakistan
- Volunteers
- 20 people
- Sponsor
- Riphah International University
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who had completed either the…
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- NCT00694109
- Testing
- Mipomersen Sodium
- Where
- 33 sites in United States, Brazil and 5 more
- Volunteers
- 144 people
- Sponsor
- Kastle Therapeutics, LLC
Healthy
A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of PF-06427878 in healthy adult…
- Trial name
- NCT02208284
- Testing
- PF-06427878
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hyperlipidemia, Cardiovascular Disease
Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia
The purpose of this trial is to re-evaluate the potential role of diet in modulating cardiovascular risk factors. If potent lipid-lowering effects through novel dietary interventions can be demonstrated, then diet may again be…
- Trial name
- NCT00438425
- Testing
- Dietary Portfolio - Intensive, Dietary Portfolio - Routine, Control (low saturated fat therapeutic diet)
- Where
- 5 sites in Canada
- Volunteers
- 351 people
- Sponsor
- University of Toronto
LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms
In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo.
- Conditions
- LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, Triglyceride Storage Type I or II Disease
- Trial name
- SOLIPARG (NCT06154408)
- Testing
- omega-3 fatty acids
- Where
- Russia
- Volunteers
- 102 people
- Sponsor
- S.LAB (SOLOWAYS)
Homozygous Familial Hypercholesterolemia
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.
- Trial name
- ODYSSEY HoFH (NCT03156621)
- Testing
- Alirocumab
- Where
- 28 sites in United States, Austria and 11 more
- Volunteers
- 69 people
- Sponsor
- Regeneron Pharmaceuticals
Cardiovascular Diseases, Hyperlipidemias
Effect of n-3 Fatty Acid Supplementation in Hyperlipidemic Patients Taking Statins
Epidemiological and clinical evidence suggests that high-dose intake of long-chain n-3 fatty acids have a favorable role in altering blood TG and non-HDL cholesterol when combined with statins in hyperlipidemic patients.
- Conditions
- Cardiovascular Diseases, Hyperlipidemias, Dyslipidemias
- Trial name
- NCT03961763
- Testing
- EPA+DHA
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- University of Chester
Hypercholesterolemia and Hyperlipidemia
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
In order to meet the preferences and needs of different patients for injection sites and improve the medication compliance of patients, it is planned to compare the bioavailability, pharmacokinetics, pharmacodynamic and safety…
- Trial name
- NCT05370950
- Testing
- SHR-1209
- Where
- China
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Cardiovascular Risk Factor, Pre Diabetes
Effects of a Workplace Exercise Intervention on Cardio-Metabolic Health
Background: The rising levels of physical inactivity in the Eastern Mediterranean region (43.2%) and in the United Arab Emirates (38%) compared with the global levels of physical inactivity (31.2%) is alarming (6,15).
- Conditions
- Cardiovascular Risk Factor, Pre Diabetes, High Blood Pressure, Elevated LDL Cholesterol
- Trial name
- NCT04403789
- Testing
- Exercise Time, Supervised Group Exercise
- Where
- United Arab Emirates
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- United Arab Emirates University
Cardiometabolic Syndrome, Obesity and Cardiovascular Risk
Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk
The increasing prevalence of obesity, its serious health consequences, and the substantial economic burden on healthcare systems underscore a pressing need for effective, long-term prevention strategies that can be implemented in…
- Conditions
- Cardiometabolic Syndrome, Obesity and Cardiovascular Risk, Overweight , Obesity
- Trial name
- NCT07806279
- Testing
- Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management
- Where
- 3 sites in Sweden
- Volunteers
- 250 people
- Sponsor
- Uppsala University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.